Related Experiment Video

Updated: Jun 8, 2026

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
09:45

Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke

Published on: March 22, 2016

Alzheimer disease prevention: focus on cardiovascular risk, not amyloid?

David S Geldmacher1

  • 1Department of Neurology, University of Virginia Health System, Charlottesville, VA, USA. Dsg8n@virginia.edu

Cleveland Clinic Journal of Medicine
|October 5, 2010
PubMed

Insights

Autosomal dominant and sporadic Alzheimer disease share pathology but differ in cause. Cardiovascular health in midlife is key for Alzheimer disease prevention, as interventions in old age are less effective.

Area of Science:

  • Neuroscience
  • Gerontology
  • Cardiovascular Medicine

Background:

  • Alzheimer disease presents in autosomal dominant (early-onset) and sporadic (late-onset) forms.
  • Both forms share common neuropathological hallmarks.
  • Cardiovascular comorbidities are recognized risk factors for Alzheimer disease development.

Purpose of the Study:

  • To explore the relationship between cardiovascular health and Alzheimer disease risk.
  • To identify optimal intervention timing for Alzheimer disease prevention.

Main Methods:

  • Review of existing literature on Alzheimer disease pathology and risk factors.
  • Analysis of evidence regarding cardiovascular comorbidities and Alzheimer disease.
  • Evaluation of intervention timing based on current scientific evidence.

Main Results:

  • While sharing pathology, Alzheimer disease forms may have distinct pathophysiological pathways.
  • Cardiovascular comorbidities significantly increase Alzheimer disease risk.
  • Evidence for preventive strategies is limited, particularly Class I evidence.

Conclusions:

  • Intervention targeting cardiovascular health is a potential strategy for Alzheimer disease risk reduction.
  • Midlife represents the most promising period for implementing preventive interventions.
  • Current evidence suggests delaying interventions until old age is less effective for Alzheimer disease prevention.

More Related Videos

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy06:27

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...